
Nick Barker
Institute of Medical Biology, Singapore
As a postdoc with Hans Clevers, Nick identified deregulation of the Wnt signalling pathway as a major initiating event in colon cancer and subsequently joined Semaia Pharmaceuticals in 2001 to develop small molecule inhibitors of the Wnt pathway as colon cancer therapeutics. In 2006, he rejoined Hans Clevers group, where he identified the Wnt target gene Lgr5 as a marker of adult stem cell populations in various organs. In 2010, Nick joined the IMB in Singapore, where he focuses on the role of Lgr5 gastric stem cells in self-renewal and cancer.
Presentation(s):
-
6/21/2018
13:15 – 13:20 -
3 - LGR5+ STEM CELLS IN EPITHELIAL MAINTENANCE, REPAIR AND CANCER OF THE MOUSE STOMACH
6/23/2018
09:50 – 10:15 -
Navigating Scientific Career Paths in Academia and Industry
6/23/2018
11:30 – 13:00